Results 1 to 10 of about 13,117,018 (331)

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)

Haematologica, 2013
Because of the very short half-life of factor VII, prophylaxis in factor VII deficiency is considered a difficult endeavor. The clinical efficacy and safety of prophylactic regimens, and indications for their use, were evaluated in factor VII-deficient ...
Mariasanta Napolitano, Muriel Giansily-Blaizot, Alberto Dolce, Jean F. Schved, Guenter Auerswald, Jørgen Ingerslev, Jens Bjerre, Carmen Altisent, Pimlak Charoenkwan, Lisa Michaels, Ampaiwan Chuansumrit, Giovanni Di Minno, Ümran Caliskan, Guglielmo Mariani   +13 more
doaj   +2 more sources

Inhibitors to factor VII in congenital factor VII deficiency [PDF]

Haemophilia, 2014
We performed a prospective study of FVII inhibitor occurrence in a large number of patients with FVII deficiency who had received replacement therapy for spontaneous or traumatic bleeding episodes, major or minor surgical interventions or prophylaxis.Inhibitor development was detected in 2.6% (3/115) of patients, but the incidence of de novo inhibitors
Batorova A, Mariani G, Kavakli K, de Saez AR, Caliskan U, Karimi M, PINOTTI, Mirko, Napolitano M, Dolce A, Sørensen B, Ingerslev J, STER Study Group   +11 more
openaire   +4 more sources

A 5-year-old Chinese boy with mild symptoms despite severe congenital factor VII deficiency: A case report [PDF]

Journal of International Medical Research
Congenital factor VII deficiency is a rare autosomal recessive bleeding disorder characterized by markedly heterogeneous clinical phenotypes and reduced plasma factor VII activity.
Wei Luo, Rong Jiang, Hongyu Jiang, Min Gong   +3 more
doaj   +2 more sources

Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab <i>in vitro</i>. [PDF]

Res Pract Thromb Haemost
Khder Y, Côté S, Hoffmann KP, Freedholm D, Bloomfield D, Connors JM.   +5 more
europepmc   +2 more sources

Planning Renal Replacement Therapy in Factor VII Deficiency. [PDF]

Kidney Int Rep
Murt A, Erol E, Ergun S, Ar MC.
europepmc   +3 more sources

Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model [PDF]

Anesthesiology, 2011
Anne Godiér, Anastasia Miclot, Bernard Le Bonniec, Marion Durand, Anne‐Marie Fischer, Joseph Emmerich, Catherine Marchand‐Leroux, Thomas Lecompte, Charles Marc Samama   +8 more
openalex   +2 more sources

Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant. [PDF]

Sci Rep
Andresen MS, Mowinckel MC, Skarpen E, Andersen E, Sandset PM, Chollet ME, Stavik B.   +6 more
europepmc   +3 more sources

Factor VII Deficiency [PDF]

Seminars in Thrombosis and Hemostasis, 2009
The complex formed between the procoagulant serine protease activated factor VII (FVII) and the membrane protein tissue factor, exposed on the vascular lumen upon injury, triggers the initiation of blood clotting. This review describes the clinical picture of FVII deficiency and provides information on diagnosis and management of the disease.
G. Mariani, BERNARDI, Francesco
openaire   +3 more sources

Hereditary Factor VII Deficiency

Definitions, 2020
rare autosomal recessive inherited blood ...

semanticscholar   +1 more source

Tissue factor pathway-related biomarkers in liver cancer: activated factor VII-antithrombin complex and tissue factor mRNA levels are associated with mortality. [PDF]

Res Pract Thromb Haemost
Martinelli N, Moruzzi S, Udali S, Castagna A, Di Santo L, Ambrosani F, Baroni M, Pattini P, Pizzolo F, Ruzzenente A, Conci S, Grusse M, Campagnaro T, Van Dreden P, Guglielmi A, Bernardi F, Olivieri O, Friso S.   +17 more
europepmc   +3 more sources